The genetic mutations observed in these patients included SCN8A, CACNA1H, and KIF1A. In the initial interval, 5 out of 8 patients with Dravet syndrome were classified as responders, a proportion that remained consistent in the subsequent two intervals, with 6 out of 8 patients showing positive response to treatment. This evidence concerns the gene SCN8A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.